GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Net Margin %

Nuvation Bio (Nuvation Bio) Net Margin % : 0.00% (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Nuvation Bio's Net Income for the three months ended in Sep. 2021 was $-21.98 Mil. Nuvation Bio's Revenue for the three months ended in Sep. 2021 was $0.00 Mil. Therefore, Nuvation Bio's net margin for the quarter that ended in Sep. 2021 was 0.00%.

The historical rank and industry rank for Nuvation Bio's Net Margin % or its related term are showing as below:


NUVB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -160.92
* Ranked among companies with meaningful Net Margin % only.

Nuvation Bio Net Margin % Historical Data

The historical data trend for Nuvation Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Net Margin % Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21
Net Margin %
- -

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Net Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Nuvation Bio's Net Margin %

For the Biotechnology subindustry, Nuvation Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvation Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Net Margin % falls into.



Nuvation Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nuvation Bio's Net Margin for the fiscal year that ended in Dec. 2020 is calculated as

Net Margin=Net Income (A: Dec. 2020 )/Revenue (A: Dec. 2020 )
=0/0
= %

Nuvation Bio's Net Margin for the quarter that ended in Sep. 2021 is calculated as

Net Margin=Net Income (Q: Sep. 2021 )/Revenue (Q: Sep. 2021 )
=-21.979/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvation Bio  (NYSE:NUVB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Nuvation Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.